U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
£ 4.9 million award to investigate pioneering biological electronics
Researchers from universities across the UK, led by the University of Bristol, have been awarded £ 4.9 million from the Biotechnology and Biological Sciences Research Council (BBSRC), the UK ’ s largest bioscience funder, to investigate how electrons and energy flow through biological molecules by building artificial protein-based wires and circuits. (Source: University of Bristol news)
Source: University of Bristol news - January 28, 2022 Category: Universities & Medical Training Tags: Announcements, Grants and Awards, Research; Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty of Science, Faculty of Science, School of Chemistry; Press Release Source Type: news
How antivirals provide hope to vulnerable Covid patients
Pfizer says its recently approved Paxlovid drug has almost 90% success in preventing severe illness if taken soon after infectionThe recent decision by regulators to approve the antiviral agent Paxlovid for use in the UK adds a formidable new weapon to the arsenal of treatments for Covid-19. Pfizer says the drug has almost 90% success in preventing severe illness in vulnerable adults if taken soon after infection occurs. Paxlovid is one of a growing repertoire of antiviral medicines – which also includes Merck’s agent Molnurpiravir – that can be given to people who have contracted the disease. Crucially, antivirals ...
Source: Guardian Unlimited Science - January 16, 2022 Category: Science Authors: Robin McKie Tags: Coronavirus Infectious diseases Medical research Microbiology Science World news Pfizer Pharmaceuticals industry Immunology Biochemistry and molecular biology Source Type: news
For Coronavirus Testing, the Nose May Not Always Be Best
As Omicron spreads, some experts are calling for a switch to saliva-based tests, which may detect infections days earlier than nasal swabs do. (Source: NYT Health)
Source: NYT Health - January 14, 2022 Category: Consumer Health News Authors: Emily Anthes Tags: your-feed-science your-feed-health Tests (Medical) Coronavirus Omicron Variant Coronavirus Delta Variant Coronavirus (2019-nCoV) Nose Throat Biology and Biochemistry Great Britain United States Source Type: news
Inside the Project to Genetically Modify Rice to Emit Fewer Greenhouse Gases
A cup of tea in 2006 changed genetic engineering forever.
Jill Banfield, a University of California at Berkeley ecosystem scientist and 1999 MacArthur Foundation fellow, had become curious in 2006 about mysterious repeating DNA sequences that were common in microbes that live in some of the planet’s most extreme environments, such as deep-sea heat vents, acid mines and geysers. She just needed a biochemist to help explain what the sequences known as Crispr/Cas9 were, and ideally somebody local.
The best scientist-location tool available to the highly decorated PhD researcher—a web search—recommended a Ber...
Source: TIME: Science - January 3, 2022 Category: Science Authors: Eric Roston / Bloomberg Tags: Uncategorized bloomberg wire climate change Food & Agriculture healthscienceclimate Source Type: news
2021 reflections: In an amazing year of achievements, nothing topped the return to campus
As we approach the end of December, it ’s a natural time to look back at the year that was. In 2021, UCLA welcomed students, faculty, staff, alumni and visitors back to our home in Westwood, though of course it wasn’t exactly the way things had been.Different from pre-pandemic times: Masks remain present. Better (much better): UCLA officially opened the Black Bruin Resource Center.Even with all the changes, UCLA persisted as a force for public good, guided by our mission of teaching, research and service. In the past year, professors continued helping us better understand our world with their research, students kept ...
Source: UCLA Newsroom: Health Sciences - December 17, 2021 Category: Universities & Medical Training Source Type: news
New institute will fund Stanford, Berkeley, UCSF scientists targeting complex human diseases
Promising $650 million in funding for scientists, the Palo Alto institute is led by Silvana Konermann, an assistant professor of biochemistry at Stanford whose work has focused on the genetic risk of neurodegenerative diseases. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 15, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Nobel Prize-winning biochemist Edmond Fischer was 'truly committed to excellence'
Fischer ’s son, retired Seattle attorney Francois “Franc” Fischer, said his father was “extremely hard-working — to the point of being obsessive about it when he was doing his research, and he was always in his lab. He always devoted time to his children and was generous with it." (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 11, 2021 Category: Biotechnology Authors: Patti Payne Source Type: news
Bristol ’ s pioneering COVID-19 research prompts French Embassy visit
Representatives from the French Embassy visited University labs today [10 Dec] to see some of the innovative COVID-19 research being undertaken at Bristol, including work on ADDomer ™ , a thermostable vaccine platform being developed by Bristol scientists to combat emerging infectious diseases. (Source: University of Bristol news)
Source: University of Bristol news - December 10, 2021 Category: Universities & Medical Training Tags: Health, Research, Business and Enterprise, International; Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Institutes, Bristol BioDesign Institute, Faculty of Science, Faculty of Science, School of Chemistry; Press Release Source Type: news
Are scientists homing in on a cure for Parkinson ’s disease?
A molecule that shows promise in preventing Parkinson’s disease has been refined by scientists at the University of Bath in the UK, and has the potential to be developed into a drug to treat the deadly neurodegenerative disease.
Professor Jody Mason, who led the research from the Department of Biology and Biochemistry at Bath, said: (Source: World Pharma News)
Source: World Pharma News - December 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
‘Amazing science’: researchers find xenobots can give rise to offspring
Xenobots are synthetic lifeforms made by cells from frog embryos and assembling them into clustersSome species do it in pairs, some without knowing the other parties involved, and some even do it on their own: when it comes to replication, nature is nothing if not versatile.Now researchers say they have found that clusters of frog cells can undergo a form of replication never before seen in plants or animals. The spherical clumps, known as xenobots, can give rise to “offspring” by sweeping up loose cells and swashing them into yet more clusters.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 29, 2021 Category: Science Authors: Nicola Davis Tags: Science Biochemistry and molecular biology Source Type: news
Walter Gratzer, Biophysical Chemist and Science Writer, Dies at 89
His career bridged impactful research in molecular biology and biochemistry with prolific science writing for academic and nonacademic audiences alike. (Source: The Scientist)
Source: The Scientist - November 23, 2021 Category: Science Tags: News & Opinion Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
